Comparing two blood thinners for cancer patients with blood clots
Part of Heart & circulation, Lungs & breathing clinical trials.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You have a confirmed blood clot, either in your leg (deep vein thrombosis) or lungs (pulmonary embolism).
- You have active cancer, meaning you are currently being treated, were diagnosed in the last 6 months, or have cancer that has not fully gone away.
- You are able to provide informed consent and are expected to live at least 6 more months.
- You must not have severe kidney or liver problems, major bleeding, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well blood thinners (anticoagulants) work in people with cancer who have had a blood clot. It aims to compare the benefits and risks of different anticoagulant medicines.
This study compares two blood-thinning medicines (apixaban pills vs. enoxaparin injections) to see which works better at preventing blood clots after head and neck cancer surgery. It may help you avoid dangerous clots without increasing bleeding risk.
This trial tests whether continuing a lower dose of blood thinners can prevent another blood clot in cancer patients who have had a clot in an arm or chest catheter. It may help find a safer way to prevent future clots.
This study tests whether a blood test and computer program can help doctors decide how long you need to take blood thinners after a cancer-related blood clot. If you've been on a blood thinner for a few months and have certain cancers, this trial may offer a more personalized approach.
This Phase 3 study tests whether the medicine rivaroxaban can prevent dangerous blood clots in people with cancer who have a central venous catheter placed recently. It may help reduce clot risk while your catheter is in place, but you must meet safety and bleeding-risk criteria.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
Hear when a new Venous Thromboembolism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.